A Phoenix Turn For Tonix: Rising From Phase III Ashes With New PTSD Approach

In an exclusive interview, Seth Lederman, CEO of New York-based Tonix Pharmaceuticals, talks about the company’s R&D rollercoaster ride and how it plans to keep its lead asset on track for approval as a treatment for post-traumatic stress disorder. 

IV1810_Tonix-Feature_244672861_1200.jpg
Rising from Phase III ashes with an action plan, Tonix will pursue lead drug in PTSD • Source: Shutterstock

It has been a bumpy journey for Tonix Pharmaceuticals Holding Corp. trying to get its lead investigational compound, TNX-102 SL, to market – despite the drug having Breakthrough Therapy status in the US for the treatment of post-traumatic stress disorder (PTSD). In an exclusive interview with In Vivo, CEO of the New York-based company, Seth Lederman, talks about Tonix’s R&D rollercoaster ride and how it hopes to keep its lead asset on track for approval.

In July 2018, Tonix was forced to stop early a Phase III trial for TNX-102 SL, also known as Tonmya...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Innovation

More from In Vivo